Results 161 to 170 of about 85,259 (288)

Editorial: Real-World Outcomes of Disease-Modifying Therapies Highlight the Need for Diagnostic Biomarkers in Early Alzheimer's Disease. [PDF]

Med Sci Monit
Parums DV.
europepmc   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source

T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus. [PDF]

J Transl Med
Chen D, Hu C, Hong Y, Xu J, Sun J, Ren J, Wu Y, Xia N, Yuan Q, Hu J, Yang T.   +10 more
europepmc   +1 more source

Biologics and Small‐Molecule Therapies in Netherton Syndrome: A Comprehensive Review

The Journal of Dermatology, EarlyView.
ABSTRACT Netherton syndrome (NS) is a rare congenital ichthyosis caused by loss‐of‐function mutations in the SPINK5 gene, leading to defective expression of the serine protease inhibitor LEKTI. Dysregulated epidermal protease activity results in impaired skin barrier function and chronic inflammation, accompanied by complex immune profiles. NS patients
Shin Morizane, Tomoyuki Mukai, Ko Sunagawa, Ken‐ichi Hasui, Anri Morita, Hayato Nomura, Mamoru Ouchida   +6 more
wiley   +1 more source

An Overview of Target Membrane Proteins for Near-Infrared Photoimmunotherapy. [PDF]

Pharmaceuticals (Basel)
Suzuki M, Hanaoka H.
europepmc   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

Allergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy, Laura Vitale, Thomas O'Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, Joel Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alvarado   +17 more
wiley   +1 more source

Establishment of a humanized mouse model of pulmonary fibrosis for advancing drug validation strategies. [PDF]

Sci Rep
Hasan MN, Chae Y, Lee SY, Kang YM.
europepmc   +1 more source

Anti‐IL‐5 Vaccination Dampens Allergen‐Specific IgE Levels and Modulates IL‐4 and IL‐5 Th2 Cytokines in Skin Allergy of Mice and Horses

Allergy, EarlyView.
This study investigates the effect of IL‐5 vaccination on allergen‐specific IgE levels, as well as mRNA and protein expression of Th1/Th2‐associated cytokines using a murine OVA skin allergy model and the naturally occurring skin allergy IBH in horses.
Fadi Jebbawi, Florian Olomski, Victoria Inversini, Giulia Keller, Tanya Rhiner, Nina Waldern, Juwela Lam, Stanislav Pantelyushin, Fabia Canonica, Katharina Birkmann, Pål Johansen, Thomas M. Kündig, Antonia Fettelschoss‐Gabriel   +12 more
wiley   +1 more source

A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (humPcMab-60) Demonstrated Antitumor Efficacy in Pancreatic and Colorectal Cancer Xenograft Models. [PDF]

Antibodies (Basel)
Suzuki H, Ohishi T, Nakamura T, Yanaka M, Handa S, Tanaka T, Kaneko MK, Kato Y.   +7 more
europepmc   +1 more source

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Allergy, EarlyView.
ABSTRACT Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment ...
Marjolein S. de Bruin‐Weller, Celeste M. Boesjes, Roselie A. Achten, Lisa A. Beck, Alan D. Irvine, Christian Vestergaard, Marlies de Graaf, Femke van Wijk, Daphne S. Bakker, Stephan Weidinger   +9 more
wiley   +1 more source